Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Icon Bioscience Reports Successful Outcomes of Phase 3 Study of IBI-10090, a Novel Sustained Release Drug Being Developed to Treat Inflammation Associated with Cataract Surgery
Icon Bioscience Reports Successful Outcomes of Phase 3 Study of IBI-10090, a Novel Sustained Release Drug Being Developed to Treat Inflammation Associated with Cataract Surgery
Icon Bioscience Reports Successful Outcomes of Phase 3 Study of IBI-10090, a Novel Sustained Release Drug Being Developed to Treat Inflammation Associated with Cataract Surgery
Submitted by
admin
on April 6, 2015 - 10:09am
Source:
Yahoo
News Tags:
ICON
IBI-10090
cataract surgery
Headline:
Icon Bioscience Reports Successful Outcomes of Phase 3 Study of IBI-10090, a Novel Sustained Release Drug Being Developed to Treat Inflammation Associated with Cataract Surgery
Do Not Allow Advertisers to Use My Personal information
